Observational Study of the EnligHTN Renal Denervation System in Europe

Inclusion Criteria: * Subject is planned to undergo a renal denervation procedure for the treatment of hypertension * Subject is ≥18 years of age at time of consent * Subject must be able and willing to provide written informed consent * Subject must be able and willing to comply with the required follow-up schedule * Subject has office SBP ≥ 140 mmHg * Subject has established hypertension (diagnosed ≥12 months prior to baseline) and is on a guideline based drug regimen at a stable (≥ 14 days) and a fully tolerated dose consisting of ≥3 anti-hypertensive medications (including 1 diuretic) Exclusion Criteria: * Subject has known significant renovascular abnormalities such as renal artery stenosis \> 30% * Subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts * Subject has a history of hemodynamically significant valvular heart disease * Subject has blood clotting abnormalities * Subject life expectancy is \< 12 months, as determined by the Study Investigator * Subject is participating in another clinical study which has the potential to impact his/her hypertension management (pharmaceutical/ device/ homeopathic) * Subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods * Subject has active systemic infection * Subject has known renal arteries with diameter(s) \< 4 mm * Subject has an estimated GFR \<45 mL/min per 1.73 m2 using the Modification of Diet in Renal Disease (MDRD) formula * Subject had a renal transplant or is awaiting a renal transplant